Opioids for refractory dyspnea

Expert Review of Respiratory Medicine

Volumn 7, Issue 2, 2013, Pages 123-135

  Mahler, Donald A ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

intensity of dyspnea; neurobiological model; neuromodulation; opioid receptors; patient reported dyspnea; unpleasantness of dyspnea

Indexed keywords

ANXIOLYTIC AGENT; BETA ENDORPHIN; CODEINE; CYTOCHROME P450 2D6; DEXTROPROPOXYPHENE; DIAMORPHINE; DIHYDROCODEINE; ENDORPHIN; FENTANYL; FENTANYL CITRATE; HYDROMORPHONE; METHADONE; MORPHINE; MULTIDRUG RESISTANCE PROTEIN; OPIATE; OPIATE RECEPTOR; OXYCODONE; OXYMORPHONE; PLACEBO; REMIFENTANIL; TRAMADOL;

ANALGESIC ACTIVITY; ANXIETY; ANXIETY DISORDER; ARTIFICIAL VENTILATION; BEHAVIOR MODIFICATION; BREATHING MUSCLE; CARBON DIOXIDE BREATHING; CAROTID BODY CHEMORECEPTOR; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFUSION; CONSTIPATION; DEPRESSION; DROWSINESS; DYSPNEA; ELECTROENCEPHALOGRAM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HALLUCINATION; HEREDITY; HUMAN; HUNGER; HYPERINFLATION; LUNG RECEPTOR; NAUSEA AND VOMITING; NEUROIMAGING; NEUROMODULATION; OXYGEN CONSUMPTION; OXYGEN SATURATION; PALLIATIVE THERAPY; PANIC; POSITRON EMISSION TOMOGRAPHY; PRIMARY SOMATOSENSORY CORTEX; PSYCHOLOGICAL ASPECT; PULMONARY REHABILITATION; RECEPTOR BINDING; REFRACTORY DYSPNEA; RELAXATION TRAINING; RESPIRATION DEPRESSION; RESPIRATORY DRIVE; REVIEW; SECONDARY SOMATOSENSORY CORTEX; SENSORY RECEPTOR; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SURVIVAL TIME; TRANSCUTANEOUS NERVE STIMULATION; TREADMILL EXERCISE; VISUAL ANALOG SCALE;

EID: 84875846556     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.13.5     Document Type: Review

References (93)

1. Mahler DA, Selecky PA, Harrod CG et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest 137(3), 674-691 (2010).
2. Parshall MB, Schwartzstein RM, Adams L et al.; American Thoracic Society Committee on Dyspnea. An offcial American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am. J. Respir. Crit. Care Med. 185(4), 435-452 (2012).
3. O'Donnell DE, Webb KA. Mechanisms of dyspnea in COPD. In: Dyspnea Mechanisms, Measurement, and Management (Volume 208). Mahler DA, O'Donnell DE (Eds). Taylor & Francis, FL, USA, 29-58 (2005).
4. Mahler DA. Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 3(3), 234-238 (2006). (Pubitemid 43668187)
5. von Leupoldt A, Dahme B. Cortical substrates for the perception of dyspnea. Chest 128(1), 345-354 (2005). (Pubitemid 40994494)
6. Davenport PW, Vovk A. Cortical and subcortical central neural pathways in respiratory sensations. Respir. Physiol. Neurobiol. 167(1), 72-86 (2009).
7. Peiffer C, Costes N, Hervé P, Garcia-Larrea L. Relief of dyspnea involves a characteristic brain activation and a specifc quality of sensation. Am. J. Respir. Crit. Care Med. 177(4), 440-449 (2008). (Pubitemid 351317588)
8. von Leupoldt A, Sommer T, Kegat S et al. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala. Am. J. Respir. Crit. Care Med. 177(9), 1026-1032 (2008). (Pubitemid 351717598)
9. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airfow limitation. The role of lung hyperinfation. Am. Rev. Respir. Dis. 148(5), 1351-1357 (1993). (Pubitemid 23326038)
10. Banzett RB, Lansing RW, Reid MB, Adams L, Brown R. Air hunger' arising from increased PCO2 in mechanically ventilated quadriplegics. Respir. Physiol 76(1), 53-67 (1989).
11. Lansing RW, Gracely RH, Banzett RB. The multiple dimensions of dyspnea: review and hypotheses. Respir. Physiol Neurobiol. 167(1), 53-60 (2009).
12. Mahler DA, Harver A, Lentine T, Scott JA, Beck K, Schwartzstein RM. Descriptors of breath lessness in cardiorespiratory diseases. Am. J. Respir. Crit. Care Med. 154(5), 1357-1363 (1996). (Pubitemid 26391181)
13. O'Donnell DE, Bertley JC, Chau LK, Webb KA. Qualitative aspects of exertional breath lessness in chronic airfow limitation: pathophysiologic mechanisms. Am. J. Respir. Crit. Care Med. 155(1), 109-115 (1997). (Pubitemid 27053150)
14. Harver A, Mahler DA, Schwartzstein RM, Baird JC. Descriptors of breath lessness in healthy individuals: distinct and separable constructs. Chest 118(3), 679-690 (2000).
15. Williams M, Cafarella P, Olds T, Petkov J, Frith P. The language of breath lessness differentiates between patients with COPD and age-matched adults. Chest 134(3), 489-496 (2008).
16. Simon PM, Schwartzstein RM, Weiss JW, Fencl V, Teghtsoonian M, Weinberger SE. Distinguishable types of dyspnea in patients with shortness of breath. Am. Rev. Respir. Dis. 142(5), 1009-1014 (1990). (Pubitemid 20384351)
17. Harver A, Mahler DA. Dyspnea: sensation, symptom, and illness. In: Dyspnea. Mahler DA (Ed.). Marcel Dekker, Inc., NY, USA, 1-34 (1998).
18. Eisner MD, Blanc PD, Yelin EH et al. Infuence of anxiety on health outcomes in COPD. Thorax 65(3), 229-234 (2010).
19. Kvaal K, Macijauskiene J, Engedal K, Laake K. High prevalence of anxiety symptoms in hospitalized geriatric patients. Int. J. Geriatr. Psychiatry 16(7), 690-693 (2001). (Pubitemid 32754928)
20. Smoller JW, Pollack MH, Otto MW, Rosenbaum JF, Kradin RL. Panic anxiety, dyspnea, and respiratory disease. Theoretical and clinical considerations. Am. J. Respir. Crit. Care Med. 154(1), 6-17 (1996). (Pubitemid 26255760)
21. von Leupoldt A, Dahme B. Psychological aspects in the perception of dyspnea in obstructive pulmonary diseases. Respir. Med. 101(3), 411-422 (2007). (Pubitemid 46196319)
22. Hill K, Geist R, Goldstein RS, Lacasse Y. Anxiety and depression in end-stage COPD. Eur. Respir. J. 31(3), 667-677 (2008).
23. Hanania NA, Müllerova H, Locantore NW et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am. J. Respir. Crit. Care Med. 183(5), 604-611 (2011).
24. Banzett RB, Mulnier HE, Murphy K, Rosen SD, Wise RJ, Adams L. Breathless-ness in humans activates insular cortex. Neuroreport 11(10), 2117-2120 (2000). (Pubitemid 30485546)
25. Evans KC, Banzett RB, Adams L, McKay L, Frackowiak RS, Corfeld DR. BOLD fMRI identifes limbic, paralimbic, and cerebellar activation during air hunger. J. Neurophysiol. 88(3), 1500-1511 (2002). (Pubitemid 35025403)
26. Peiffer C, Poline JB, Thivard L, Aubier M, Samson Y Neural substrates for the perception of acutely induced dyspnea. Am. J. Respir. Crit. Care Med. 163(4), 951-957 (2001). (Pubitemid 32275870)
27. Bellofore S, Di Maria GU, Privitera S, Sapienza S, Milic-Emili J, Mistretta A. Endogenous opioids modulate the increase in ventilatory output and dyspnea during severe acute bronchoconstriction. Am. Rev. Respir. Dis. 142(4), 812-816 (1990). (Pubitemid 20344649)
28. Mahler DA, Murray JA, Waterman LA et al Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD. Eur. Respir. J. 33(4), 771-777 (2009).
29. Gifford AH, Mahler DA, Waterman LA et al. Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breath lessness during resistive load breathing in COPD. COPD 8(3), 160-166 (2011).
30. Bausewein C, Farquhar M, Booth S, Gysels M, Higginson IJ. Measurement of breath lessness in advanced disease: a systematic review. Respir. Med. 101(3), 399-410 (2007). (Pubitemid 46205909)
31. Edmonds P, Karlsen S, Khan S, Adding-ton-Hall J. A comparison of the palliative care needs of patients dying from chronic respiratory diseases and lung cancer. Palliat. Med. 15(4), 287-295 (2001). (Pubitemid 32640547)
32. Feng Y, He X, Yang Y, Chao D, Lazarus LH, Xia Y Current research on opioid receptor function. Curr. Drug Targets 13(2), 230-246 (2012).
33. Hughes J, Kosterlitz HW Opioid Peptides: introduction. Br. Med. Bull. 39(1), 1-3 (1983).
34. Stein C, Lang LJ. Peripheral mechanisms of opioid analgesia. Curr. Opin. Pharmacol 9(1), 3-8 (2009).
35. Millan MJ. Multiple opioid systems and pain. Pain 27(3), 303-347 (1986). (Pubitemid 17226872)
36. Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax 57(11), 939-944 (2002). (Pubitemid 35316271)
37. Weil JV, McCullough RE, Kline JS, Sodal IE. Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. N. Engl. J. Med. 292(21), 1103-1106 (1975).
38. Eckenhoff JE, Oech SR. The effects of narcotics and antagonists upon respiration and circulation in man. A review. Clin. Pharmacol. Ther. 1, 483-524 (1960).
39. Schlaepfer TE, Strain EC, Greenberg BD et al. Site of opioid action in the human brain: μ and κ agonists' subjective and cerebral blood fow effects. Am. J. Psychiatry 155(4), 470-473 (1998). (Pubitemid 28207440)
40. Leppä M, Korvenoja A, Carlson S et al. Acute opioid effects on human brain as revealed by functional magnetic resonance imaging. Neuroimage 31(2), 661-669 (2006). (Pubitemid 43776689)
41. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia - imaging a shared neuronal network. Science 295(5560), 1737-1740 (2002). (Pubitemid 34202913)
42. Pattinson KT, Governo RJ, MacIntosh BJ et al. Opioids depress cortical centers responsible for the volitional control of respiration. J. Neurosci. 29 (25), 8177- 8186 (2009).
43. Firestone LL, Gyulai F, Mintun M, Adler LJ, Urso K, Winter PM. Human brain activity response to fentanyl imaged by positron emission tomography. Anesth. Analg. 82(6), 1247-1251 (1996). (Pubitemid 26158009)
44. Zebraski SE, Kochenash SM, Raffa RB. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci. 66(23), 2221-2231 (2000). (Pubitemid 30256621)
45. Mahler DA, Gifford AH, Waterman LA et al. Effect of increased blood levels of beta-endorphin on perception of breathless-ness. Chest doi :10.1378/chest.12-1541 (2012) (Epub ahead of print).
46. Banzett RB, Adams L, O'Donnell CR, Gilman SA, Lansing RW, Schwartzstein RM. Using laboratory models to test treatment: morphine reduces dyspnea and hypercapnic ventilatory response. Am. J. Respir. Crit. Care Med. 184(8), 920-927 (2011).
47. Banzett RB, Moosavi SH. Dyspnea and pain: similarities and contrasts between two very unpleasant sensations. APS Bulletin 11, 1-8 (2001).
48. Horton R, Rocker G. Contemporary issues in refractory dyspnoea in advanced chronic obstructive pulmonary disease. Curr. Opin. Support. Palliat. Care 4(2), 56-62 (2010).
49. Williams AL. Drug Facts and Comparisons. Wolters Kluwer Health, MI, USA, 1315-1317 (2012).
50. Powell DR, Hartley PH. Diseases of the Lungs and Pleurae. HK Lewis, London, UK (1911).
51. Reigl F. Diseases of the respiratory organs. In: Cyclopedia of Medical Practice (Volume 4). Von Ziemsen H (Ed.). Samson Law, London, UK, 523-586 (1876).
52. West S. Diseases of the Organs of Respiration (Volume 1). Charles Griffn, London, UK (1909).
53. Woodcock AA, Gross ER, Gellert A, Shah S, Johnson M, Geddes DM. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N. Engl. J. Med. 305(27), 1611-1616 (1981). (Pubitemid 12169189)
54. Johnson MA, Woodcock AA, Geddes DM. Dihydrocodeine for breath lessness in 'pink puffers'. Br. Med. J. (Clin. Res. Ed). 286(6366), 675-677 (1983). (Pubitemid 13147653)
55. Abernethy AP, Currow DC, Frith P, Fazekas BS, McHugh A, Bui C. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 327(7414), 523-528 (2003).
56. Johnson MJ, McDonagh TA, Harkness A, McKay SE, Dargie HJ. Morphine for the relief of breathlessness in patients with chronic heart failure - a pilot study. Eur. J. Heart Fail. 4(6), 753-756 (2002). (Pubitemid 35403084)
57. Oxberry SG, Torgerson DJ, Bland JM, Clark AL, Cleland JG, Johnson MJ. Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. Eur. J. Heart Fail. 13(9), 1006-1012 (2011).
58. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Interventions for alleviating cancer-related dyspnea: a systematic review and meta-analysis. Acta Oncol. 51(8), 996-1008 (2012).
59. Jensen D, Alsuhail A, Viola R, Dudgeon DJ, Webb KA, O'Donnell DE. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. J. Pain Symptom Manage. 43(4), 706-719 (2012).
60. Shohrati M, Ghanei M, Harandi AA, Foroghi S, Harandi AA. Effect of nebulized morphine on dyspnea of mustard gas-exposed patients: a double-blind randomized clinical trial study. Pulm. Med. 2012, 610921 (2012).
61. Lanken PN, Terry PB, Delisser HM et al.; ATS End-of-Life Care Task Force. An offcial American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am. J. Respir. Crit. Care Med. 177(8), 912-927 (2008). (Pubitemid 351600670)
62. Oxberry SG, Jones L, Clark AL, Johnson MJ. Attitudes to morphine in chronic heart failure patients. Postgrad. Med. J. 88(1043), 515-521 (2012).
63. Marciniuk DD, Goodridge D, Hernandez P et al.; Canadian Thoracic Society COPD Committee Dyspnea Expert Working Group. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can. Respir. J. 18(2), 69-78 (2011).
64. Qaseem A, Wilt TJ, Weinberger SE et al.; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann. Intern. Med. 155(3), 179 -191 (2011).
65. Clemens KE, Klaschik E. Symptomatic therapy of dyspnea with strong opioids and its effect on ventilation in palliative care patients. J. Pain Symptom Manage. 33(4), 473 - 481 (2007). (Pubitemid 46482946)
66. Clemens KE, Quednau I, Klaschik E. Is there a higher risk of respiratory depression in opioid-naive palliative care patients during symptomatic therapy of dyspnea with strong opioids? J. Palliat. Med. 11 (2), 204-216 (2008). (Pubitemid 351374202)
67. Chan JD, Treece PD, Engelberg RA et al. Narcotic and benzodiazepine use after withdrawal of life support: association with time to death? Chest 126(1), 286-293 (2004). (Pubitemid 38943148)
68. Daly BJ, Thomas D, Dyer MA. Procedures used in withdrawal of mechanical ventilation. Am. J. Crit. Care 5(5), 331-338 (1996). (Pubitemid 126484550)
69. Stone P, Phillips C, Spruyt O, Waight C. A comparison of the use of sedatives in a hospital support team and in a hospice. Palliat. Med. 11(2), 140-144 (1997). (Pubitemid 27170619)
70. Thorns A, Sykes N. Opioid use in last week of life and implications for end-of-life decision-making. Lancet 356(9227), 398-399 (2000). (Pubitemid 30487499)
71. Bar-Or D, Marx JA, Good J. Breathless-ness, alcohol, and opiates. N. Engl. J. Med. 306(22), 1363-1364 (1982).
72. Rocker G, Young J, Donahue M, Farquhar M, Simpson C. Perspectives of patients, family caregivers and physicians about the use of opioids for refractory dyspnea in advanced chronic obstructive pulmonary disease. CMAJ 184(9), E497-E504 (2012).
73. Horton R, Rocker G, Currow D. The dyspnea target: can we zero in on opioid responsiveness in advanced chronic obstructive pulmonary disease? Curr. Opin. Support. Palliat. Care 4(2), 92-96 (2010).
74. Mahler DA, Waterman LA, Ward J, McCusker C, ZuWallack R, Baird JC. Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes. Chest 132(4), 1283-1290 (2007). (Pubitemid 47621005)
75. Mularski RA, Campbell ML, Asch SM et al. A review of quality of care evaluation for the palliation of dyspnea. Am. J. Respir. Crit. Care Med. 181(6), 534-538 (2010).
76. Rocker G, Horton R, Currow D, Goodridge D, Young J, Booth S. Palliation of dyspnoea in advanced COPD: revisiting a role for opioids. Thorax 64(10), 910-915 (2009).
77. Johnson MJ, Bland JM, Oxberry SG, Abernethy AP, Currow DC. Opioids for chronic refractory breathlessness: patient predictors of benefcial response. Eur. Respir. J. doi: 10.1183/09031936.00139812 (2012) (Epub ahead of print).
78. Currow DC, McDonald C, Oaten S et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J. Pain Symptom Manage. 42(3), 388-399 (2011).
79. Cohen MH, Anderson AJ, Krasnow SH et al. Continuous intravenous infusion of morphine for severe dyspnea. South. Med. J. 84(2), 229-234 (1991).
80. Gomutbutra P, O'Riordan DL, Pantilat SZ. Management of moderate-to-severe dyspnea in hospitalized patients receiving palliative care. J. Pain Symptom Manage. doi:10.1016/j.jpainsymman.2012.05.004 (2012) (Epub ahead of print).
81. Johnson MJ, Abernethy AP, Currow DC. Gaps in the evidence base of opioids for refractory breathlessness. A future work plan? J. Pain Symptom Manage. 43(3), 614-624 (2012).
82. Ngai SP, Jones AY, Hui-Chan CW, Yu HP. Acute effects of Acu-TENS on FEV1 and blood ß-endorphin level in chronic obstructive pulmonary disease. Altern. Ther. Health Med. 17(5), 8-13 (2011).
83. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin. Pharmacol. Ther. 81(3), 429-444 (2007). (Pubitemid 46364493)
84. Pasternak GW Molecular insights into μ opioid pharmacology: from the clinic to the bench. Clin. J. Pain 26(Suppl. 10), S3-S9 (2010).
85. Persson K, Sjöström S, Sigurdardottir I, Molnár V, Hammarlund-Udenaes M, Rane A. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. Br. J. Clin. Pharmacol. 39(2), 182-186 (1995).
86. Ventura C, Bastagli L, Bernardi P, Caldarera CM, Guarnieri C. Opioid receptors in rat cardiac sarcolemma: effect of phenylephrine and isoproterenol. Biochim. Biophys. Acta 987(1), 69-74 (1989). (Pubitemid 20008999)
87. Gift AG. Visual analogue scales: measurement of subjective phenomena. Nurs. Res. 38(5), 286-288 (1989). (Pubitemid 19247822)
88. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 93(3), 580-586 (1988).
89. Gift AG, Narsavage G. Validity of the numeric rating scale as a measure of dyspnea. Am. J. Crit. Care 7(3), 200-204 (1998). (Pubitemid 128460535)
90. Borg GA. Psychophysical bases of perceived exertion. Med. Sci. Sports Exerc. 14(5), 377-381 (1982). (Pubitemid 13215050)
91. Booth S, Bausewein C, Higginson I, Moosavi SH. Pharmacological treatment of refractory breathlessness. Expert Rev. Respir. Med. 3(1), 21-36 (2009).
92. Dudgeon D. Management of dyspnea at the end of life. In: Dyspnea. Mahler DA, O'Donnell DE (Eds). Taylor & Francis, NY, USA, 429-461 (2005).
93. Nici L, Donner C, Wouters E et al.; ATS/ERS Pulmonary Rehabilitation Writing Committee. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 173(12), 1390-1413 (2006). (Pubitemid 43900715)